| Quality Standard | ICH Q7, ICH Q10 |
|---|---|
| GMP Framework | NMPA, FDA, EU GMP |
| Pharmacopoeia | USP, EP, ChP |
| Documentation Package | CoA + MSDS + Stability Data + 3rd-Party Test Reports |
| Audit Frequency | Annual on-site + periodic remote |
| Quality System | ISO 9001-aligned QMS |
Pharmaceutical API procurement depends on a structured quality assurance framework that extends from factory qualification through final shipment verification. For procurement managers and quality assurance teams sourcing API from China, understanding the depth and rigor of a supplier's quality management system is the difference between reliable supply and regulatory exposure. KingWish operates an integrated quality assurance process built on GMP standards, ICH guidelines, and years of practical experience in china pharmaceutical quality control procedure.
KingWish approaches quality management as a continuous, end-to-end system rather than a checkpoint at the end of production. The quality of a pharmaceutical API is determined by decisions made weeks before the first batch is produced: which manufacturing partner is selected, what quality agreement governs the relationship, how the factory audit was conducted, and what testing and release protocols are in place. Every subsequent step builds on these foundational decisions.
Our quality philosophy rests on three principles. First, quality by design upstream: selecting manufacturing partners whose facilities, quality systems, and regulatory standing meet the target market requirements before production begins. Second, verification at every stage: in-process quality control during production, finished product testing against pharmacopoeia monograph, and third-party laboratory verification for independent confirmation. Third, documentation that travels with the product: every shipment of API we supply includes a complete quality documentation package (CoA, MSDS, stability data, and third-party test reports) so that buyers have full traceability from raw material to finished API.
This philosophy distinguishes api quality management china from transactional sourcing models. A buyer who purchases API based on price and CoA alone accepts unknown residual risk. A buyer who sources through a partner with a documented, auditable china api quality system gains supply chain transparency and regulatory defensibility. At KingWish, quality is not an inspection step at the warehouse door; it is the organizing principle for how we select factories, structure supply agreements, monitor production, and prepare every shipment.
Supplier selection is the most consequential quality decision in the API supply chain. A well-run quality assurance system downstream cannot compensate for a manufacturing partner whose facility, quality culture, or regulatory standing is inadequate. KingWish applies a structured, multi-criteria supplier selection process that screens potential manufacturing partners before any commercial relationship begins. This china api supplier quality verification process is designed to eliminate facilities that do not meet the minimum standards required for pharmaceutical-grade API production.
Every KingWish manufacturing partner must meet baseline criteria before entering our supplier qualification pipeline. The facility must hold a current Drug Manufacturing License (DML) issued by NMPA for the specific API category. The facility must operate under a GMP-compliant quality management system, evidenced by a valid GMP certificate from NMPA or an internationally recognized authority. The production lines used for our products must be dedicated or must have validated cleaning procedures that prevent cross-contamination between different APIs, particularly relevant for steroid APIs and other potent compounds where trace carryover could affect product quality. The facility must have a functioning quality control laboratory equipped with HPLC, GC, IR spectroscopy, and other instrumentation required for pharmacopoeia testing. Finally, the facility must have no unresolved enforcement actions from FDA, EDQM, or other major regulatory authorities within the preceding three years.
Beyond these minimum criteria, we evaluate structural factors that affect long-term supply reliability. The facility's production capacity relative to our projected order volumes, the redundancy of critical equipment (a single HPLC in a QC lab is a single point of failure), and the depth of the quality unit (a quality head supported by one analyst is insufficient for a facility producing multiple APIs) all factor into the selection decision. Facilities that meet the minimum criteria but lack structural depth are placed on a development track with more frequent audit monitoring if selected.
GMP certificate validation at KingWish follows a standardized procedure that goes beyond accepting the certificate document at face value. We verify the issuing authority: NMPA certificates are cross-referenced against the provincial drug administration's inspection database where available, and international GMP certificates (EU GMP, FDA inspection outcomes) are verified against the issuing authority's public database (EudraGMDP for EU GMP certificates, FDA inspection classification database for FDA inspection outcomes). We verify that the certificate scope covers the specific API and production processes relevant to our sourcing requirements. A GMP certificate for oral solid dosage forms does not cover API manufacturing, and a certificate for fermentation-derived APIs does not necessarily cover synthetic APIs produced at the same facility.
We verify certificate validity including issue date, expiry date, and any conditions or limitations noted on the certificate. A GMP certificate with outstanding observations that have not been resolved within the authority's specified timeframe is treated as if expired. We also verify that the legal entity named on the GMP certificate matches the legal entity that will manufacture our product. In China, it is common for a manufacturing site to operate under a different legal entity name than the trading company; KingWish documents the legal relationship between entity names and retains this verification in the supplier qualification file. For facilities supplying the European market, we verify CEP status through the EDQM certification database as part of the china api supplier quality verification process.
Regulatory filings are among the strongest independent indicators of a manufacturing partner's quality system maturity. A facility that has prepared and maintained a Type II DMF with the FDA or a CEP with the EDQM has subjected its manufacturing process, quality controls, and facility documentation to regulatory scrutiny. KingWish prioritizes manufacturers with active, in-good-standing filings because these filings demonstrate not only technical capability but also the organizational discipline to maintain compliance documentation over multiple regulatory cycles.
For US-market products, we require the manufacturing partner to hold an active Type II DMF. We verify DMF status on the FDA DMF database and confirm that the DMF holder name matches the legal entity. We also check the FDA warning letter database and import alert database for the facility. For EU-market products, we prioritize manufacturers holding a valid CEP, verified through the EDQM certification database. A CEP that has undergone multiple revision cycles (indicating active maintenance) is a positive signal of regulatory engagement. For further detail on regulatory filing requirements, see our DMF, CEP, and GMP Buyers Guide.
Financial stability is a quality-relevant supplier criterion that is frequently overlooked. A manufacturing partner experiencing financial distress may reduce quality system investment, defer equipment maintenance, or lose qualified personnel, all of which degrade product quality over time. KingWish evaluates supplier financial stability through business license verification, production site ownership or long-term lease documentation, and public financial records where available. We also assess business continuity risk by evaluating the supplier's customer concentration (a manufacturer dependent on a single large customer carries higher continuity risk than one with a diversified customer base) and geographic market diversification (manufacturers serving only the domestic Chinese market may lack the quality system rigor required for regulated export markets).
For critical manufacturing partners, we maintain documented contingency plans including qualified alternative suppliers for each API category. This ensures that a disruption at one manufacturing site does not interrupt supply to our customers. The contingency qualification process mirrors the primary supplier selection process; a backup supplier must meet the same minimum criteria and undergo the same audit protocol as a primary supplier before being designated as a qualified alternative.
The factory audit is the most comprehensive element of the china api factory audit process. KingWish conducts on-site audits of every manufacturing partner before qualification and at annual intervals thereafter. Our audit protocol follows ICH Q7 guidelines for API manufacturing and includes specific modules tailored to the pharmaceutical trading company's perspective: we audit not only the manufacturer's internal quality system but also how the manufacturer interfaces with external parties (customers, testing laboratories, logistics providers), because gaps at these interfaces are a common source of quality failures in international API trade.
Before scheduling an on-site visit, KingWish sends a detailed pre-audit questionnaire to the prospective manufacturing partner. The questionnaire covers organizational structure and quality unit reporting relationships, facility overview including layout, cleanroom classification, and utilities (HVAC, water system, compressed air), product portfolio and whether the API of interest is manufactured in dedicated or shared equipment, quality management system documentation including SOP index, change control log summary, and deviation/CAPA trending data, regulatory filing status with filing numbers and most recent authority correspondence dates, and analytical capabilities including instrument list, analyst count, and method validation summary.
The completed questionnaire serves three purposes. It allows advance identification of potential gaps that require deeper investigation during the on-site visit. It tests the manufacturer's responsiveness and documentation discipline; a manufacturer that takes weeks to return a questionnaire or provides incomplete answers is unlikely to perform better on batch documentation turnaround. And it provides documented evidence of the supplier qualification process for our own quality system records. The questionnaire responses are reviewed by KingWish quality personnel before the audit is scheduled, and any areas of concern are flagged for specific attention during the on-site walkthrough.
The on-site audit follows a structured checklist aligned with ICH Q7 chapters. The physical walkthrough covers the manufacturing areas, starting from material receipt and sampling through production, packaging, and finished product warehousing. In the production area, we observe equipment condition and cleanliness, the state of in-process labeling and material identification, operator practices including gowning and hygiene, and whether environmental monitoring is being conducted as specified. Equipment that appears unused but is claimed to be in active production, or production areas that are visibly cleaner or better organized than other areas of the facility, may indicate that only selected areas were prepared for the audit, which is itself a quality culture concern.
In the quality control laboratory, we observe sample handling and labeling, instrument condition and calibration status, working reference standard management, analyst technique and whether analysts are following written procedures or relying on memory, and data integrity controls including audit trails and user access management. A laboratory with hand-written results on loose paper later transcribed into electronic systems, or with shared user accounts on analytical instruments, has fundamental data integrity gaps that may compromise the reliability of all test results. The warehouse walkthrough evaluates material segregation (quarantine, released, rejected), storage conditions including temperature and humidity monitoring, pest control, and whether drum and container seals are intact. For a china gmp partner factory audit, these physical observations often reveal more about the quality culture than documentation review alone.
The documentation review component of the audit examines the quality system's written framework and its operational implementation. We review the quality manual and site master file for overall quality system architecture. We review a sample of batch manufacturing records for completeness, contemporaneous data entry, deviation documentation, and the review and approval process. Incomplete batch records, late entries, or records that lack evidence of second-person verification indicate a documentation culture that would not withstand regulatory inspection.
We review the change control log for the preceding 12 months and select specific changes to trace through the system: was the change properly justified, evaluated for impact on product quality, approved before implementation, and verified after implementation? We review the deviation and CAPA log, selecting a sample of deviations to assess whether root cause investigations were substantive, whether corrective actions were implemented and verified as effective, and whether CAPA timelines were met. We review the annual product quality review for the API of interest, which should consolidate batch data trending, deviation summaries, change control summaries, and stability data into a quality assessment.
Personnel competence is a leading indicator of quality system health. KingWish reviews the training program structure including initial qualification training, job-specific SOP training, and ongoing GMP refresher training. We verify that training records are maintained for all personnel whose work affects product quality and that training is documented before personnel perform tasks independently. Training records that show a single signature for multiple SOPs on the same date, or training conducted after the date the person began performing the task, suggest a training system that exists on paper but not in practice.
We interview key personnel during the audit, including the quality unit head, production manager, and QC laboratory supervisor. In these interviews, we assess not only technical knowledge but also the individual's understanding of their quality responsibilities. A quality head who defers all quality decisions to the general manager, or a production manager who cannot explain the critical process parameters for their product, reveals gaps that documentation review alone may not surface. The china pharmaceutical quality control procedure depends on competent personnel executing written procedures correctly and consistently; training and qualification assessment verifies that this foundation is in place.
Equipment qualification (IQ/OQ/PQ) and ongoing calibration provide the physical foundation for manufacturing consistency and analytical accuracy. KingWish reviews the equipment qualification status for critical production equipment (reactors, centrifuges, dryers, mills) and analytical instruments (HPLC, GC, balances, dissolution apparatus). We verify that qualification protocols were approved before execution, that acceptance criteria were defined and met, and that requalification is performed on a defined schedule or after significant changes.
For calibration, we review the calibration schedule and verify that all instruments requiring calibration are included. We check calibration records for a sample of instruments, confirming that calibration standards are traceable to national or international standards, that out-of-calibration results triggered an investigation of the impact on previous test results, and that calibration frequencies are justified. An HPLC with a calibration certificate dated more than twelve months prior, or a balance used daily but calibrated quarterly, indicates a calibration program that may not detect instrument drift in time to prevent unreliable test results from being used for batch release decisions.
Batch testing and release is the verification step that confirms the manufacturing process has produced API meeting pharmacopoeia specifications. KingWish integrates testing checkpoints at multiple stages of production and distribution to ensure that quality is confirmed, not assumed, before any batch reaches a customer.
In-process quality control (IPQC) monitors the manufacturing process at defined control points during production rather than waiting for finished product testing to detect quality issues. For synthetic API manufacturing, IPQC typically includes reaction monitoring by TLC or HPLC at key synthetic steps to confirm reaction completion, intermediate purity testing before proceeding to the next synthetic step, in-process checks of critical process parameters (temperature, pH, reaction time) against validated ranges, and yield calculations at each step to detect process deviations early. The china api quality system relies on IPQC data to make real-time production decisions: if an intermediate fails to meet the in-process specification, the batch is held for investigation rather than being carried forward where the defect may become harder to detect or correct.
KingWish reviews the manufacturing partner's IPQC program as part of the supplier qualification and annual audit cycle. We verify that IPQC sampling plans are defined, that in-process specifications are based on process validation data, and that IPQC results are recorded contemporaneously in batch records. A manufacturer who performs IPQC testing but records results after the batch is complete rather than during production is not operating true in-process control; the data may be accurate, but the opportunity to intervene in a trending process deviation has been lost.
Finished product testing is conducted against the relevant pharmacopoeia monograph (USP, EP, or ChP, depending on the target market). The testing package includes identity confirmation by IR spectroscopy and/or a specific chemical identification test, assay by HPLC against a qualified reference standard (typically USP or EP reference standard), related substances and impurity profile by HPLC with the method specified in the monograph, residual solvents by GC headspace analysis per ICH Q3C, loss on drying or water content by Karl Fischer titration, specific optical rotation where applicable, heavy metals or elemental impurities per ICH Q3D, and microbial limits testing. Each test is performed using a validated analytical method, and results are recorded in a certificate of analysis (CoA) that accompanies the batch.
KingWish reviews the CoA for every batch before shipment release. Our review extends beyond checking that results fall within specification limits; we trend results against previous batches from the same manufacturer to detect shifts in the impurity profile, assay value, or other parameters that may indicate process drift even when individual results remain within specification. A batch with an assay of 99.1% when the previous ten batches averaged 99.8% is within specification, but the downward trend warrants investigation. This trending analysis is a distinguishing feature of the china pharmaceutical quality control procedure we apply to every batch we supply.
KingWish requires that every batch of API we supply is supported by retention samples held by the manufacturer for the period specified by applicable GMP regulations (typically one year after the expiry date of the batch, or longer if specified by the customer's regulatory requirements). Retention samples are stored under the labeled storage conditions in containers that are identical or equivalent to the marketed container closure system. The retention sample quantity must be sufficient to perform full pharmacopoeia testing at least twice, allowing for investigation of any quality complaint or out-of-specification result that may arise after the batch has been released and distributed.
We verify the retention sample program during factory audits by physically inspecting the retention sample storage area, confirming that samples are labeled with batch number, storage condition, and retention period, and checking that the retention sample inventory matches the list of batches produced and released. A retention sample area where samples are disorganized, unlabeled, or stored under conditions different from those specified on the label indicates a retention program that would not reliably support post-market quality investigations.
As an additional layer of quality assurance, KingWish engages ISO 17025-accredited third-party laboratories to perform independent testing on selected batches. Third-party verification serves multiple purposes: it provides an independent confirmation of the manufacturer's CoA results, it detects systematic laboratory bias or method issues at the manufacturer that may not be apparent from internal results alone, and it provides buyers with documented third-party quality evidence that strengthens their own regulatory submissions. Third-party testing is conducted on the first commercial batch from a new manufacturing partner, on a periodic basis for established partners (typically every third to fifth batch), and whenever the manufacturer's CoA results show an unusual trend or a specification result near the acceptance limit.
When third-party results differ from the manufacturer's CoA results, KingWish initiates a laboratory investigation to determine the root cause before releasing the batch. The investigation considers sample handling and transport conditions, method differences between the two laboratories, reference standard differences, and potential systematic bias. The batch is not released until the discrepancy is resolved and the release specification is confirmed. This independent verification layer is a cornerstone of our api shipment quality inspection process.
Documentation is the physical evidence of quality assurance that travels with the product. A batch of API without complete, accurate documentation is of limited regulatory value regardless of its analytical quality. KingWish has standardized the documentation package for every API shipment to include six core documents, each serving a specific function in the buyer's quality assurance, regulatory compliance, and supply chain management processes.
The Certificate of Analysis (CoA) is the primary quality document, listing test results against pharmacopoeia specifications for the specific batch being shipped. The CoA must be batch-specific; a generic or "typical" CoA is not acceptable for batch release. The Material Safety Data Sheet (MSDS) provides safety, handling, storage, and emergency response information required for workplace safety compliance and customs clearance. The GMP certificate copy demonstrates that the manufacturing facility holds current GMP certification from a recognized authority. For US-market products, the DMF authorization letter confirms the buyer's right to reference the DMF in their ANDA/NDA. For EU-market products, the CEP reference letter provides the CEP number and confirms that the specific batch was manufactured under the CEP scope. Stability data summary provides accelerated and long-term stability study results supporting the assigned retest period or expiry date. Third-party test reports, when applicable, provide independent analytical confirmation of the CoA results.
Beyond these six core documents, KingWish can provide additional documentation based on the buyer's specific regulatory requirements, including Certificate of Origin, Free Sale Certificate, Certificate of Pharmaceutical Product (CPP), and documentation required by destination-country health authorities. Documentation is reviewed for accuracy and completeness before being released to the buyer, and a documentation checklist is maintained in the batch record to confirm that all required documents have been included. Our approach to documentation excellence is further detailed in our API Quality Documentation Guide.
Supply chain traceability is the ability to trace every batch of API back through the manufacturing process to the raw materials and starting materials from which it was produced. Traceability is a GMP requirement under ICH Q7 and is essential for investigating quality issues, managing recalls, and demonstrating supply chain integrity to regulatory authorities. KingWish maintains traceability records that link each batch of API we supply to the specific batches of starting materials, intermediates, and reagents used in its manufacture.
Our traceability system begins with starting material qualification. Each starting material supplier used by our manufacturing partners undergoes a vendor qualification process that includes supplier audit (conducted by the API manufacturer or by KingWish directly for critical starting materials), certificate of analysis review for each received lot, and identity testing upon receipt. The batch manufacturing record for each API batch references the specific lots of starting materials consumed, creating an unbroken chain of documentation from starting material receipt through finished API shipment.
The china api quality system requires that this traceability extends forward as well as backward. KingWish maintains distribution records that identify which customers received which batches of API, enabling targeted communication in the event of a quality issue. In the event of a recall, our traceability system can identify all affected shipments within hours, and our customer notification protocol (described in Section 7.4) ensures that affected buyers are informed promptly with complete information about the quality issue, the affected batch numbers, and the recommended actions.
A quality system is defined not only by how it prevents quality issues but by how it responds when issues occur. KingWish maintains a structured CAPA (Corrective and Preventive Action) process for handling non-conformances, whether identified internally during batch review or externally through customer feedback. The process follows the plan-do-check-act cycle and is designed to address the root cause of quality issues rather than treating symptoms.
When a batch test result falls outside the specification limit, KingWish initiates a formal out-of-specification (OOS) investigation in accordance with FDA guidance for industry on OOS investigations. The investigation proceeds in two phases. Phase 1 is a laboratory investigation to determine whether the OOS result is attributable to laboratory error: was the correct sample tested, was the method followed correctly, were instrument performance and system suitability acceptable, was the calculation correct? If a laboratory error is identified and the result is invalidated, the test is repeated with the original sample and the original result, the investigation finding, and the retest result are all documented. If no laboratory error is identified, the OOS is confirmed and the investigation advances to Phase 2.
Phase 2 is a full-scale investigation that examines the manufacturing process, raw materials, equipment, environment, and personnel to identify the root cause of the confirmed OOS result. The investigation involves a cross-functional team including quality assurance, production, and quality control personnel. The batch is not released until the investigation is completed, the root cause is identified, and a disposition decision (release, reprocess, or reject) is made based on the investigation findings.
Root cause analysis is the core problem-solving methodology in KingWish's CAPA process. We apply structured analysis techniques including 5-Why analysis, fishbone (Ishikawa) diagrams, and fault tree analysis depending on the complexity of the quality issue. The objective is to identify the fundamental cause of the non-conformance, not the immediate or proximate cause. A batch that fails assay specification because the reactor temperature exceeded the validated range has an immediate cause (temperature deviation), but the root cause may be a failed temperature controller, an operator who was not trained on the temperature alarm response procedure, or a process validation that did not adequately define the temperature range.
The quality of root cause analysis is assessed by whether the identified root cause, if corrected, would prevent recurrence of the non-conformance. If the proposed root cause would not break the chain of causation that led to the failure, the analysis is incomplete and requires further investigation. KingWish quality personnel review the root cause analysis for every non-conformance to ensure that the identified root cause is specific, actionable, and supported by evidence, not speculation.
CAPA (Corrective and Preventive Action) implementation translates root cause findings into specific actions that correct the immediate non-conformance and prevent recurrence. Corrective actions address the identified root cause of the specific non-conformance: if the root cause was an inadequate operator training program, the corrective action includes revising the training procedure and retraining all affected operators. Preventive actions extend the corrective action to prevent similar non-conformances in other products, processes, or areas: if the training gap was identified in one production area, the preventive action includes reviewing training programs in all production areas for similar gaps.
Each CAPA is assigned to a responsible person with a defined due date. CAPA status is tracked through a log that is reviewed at management review meetings. Effectiveness verification is a mandatory step: after CAPA implementation, a defined period of monitoring (typically three to six months or a specified number of batches) confirms that the non-conformance does not recur. If recurrence is observed during the effectiveness verification period, the CAPA is reopened and the root cause analysis is revisited. A CAPA that is closed without effectiveness verification has not demonstrated that it achieved its objective, and KingWish does not close CAPAs until effectiveness is confirmed.
When a non-conformance is identified that affects a batch that has already been shipped to a customer, KingWish follows a defined customer notification protocol. Notification is made within five business days of confirming that the non-conformance affects shipped product. The notification includes the batch number and quantity affected, a description of the non-conformance and its potential impact on product quality, the investigation status and findings to date, a recommendation for action (quarantine, return, additional testing, or other disposition), and contact information for the KingWish quality representative managing the investigation.
Transparency in customer notification is a core value at KingWish. We notify customers of quality issues even when the issue does not create a health risk or regulatory reporting obligation, because we believe that customers have a right to full information about the products they have purchased. Delayed or incomplete notification damages the trust that is the foundation of the supplier-buyer relationship in pharmaceutical supply chains. Our approach to handling non-conformances is consistent with the quality management principles described in the About KingWish page.
KingWish quality assurance extends beyond product supply to include ongoing quality support for our customers. When a buyer engages KingWish as their API procurement partner, they gain access to quality support services that supplement their own quality assurance capabilities and reduce the burden of managing multiple supplier quality relationships.
Pre-purchase quality consultation is the starting point. We provide regulatory filing verification for the specific API and target market, review pharmacopoeia specification requirements, and advise on documentation requirements for import registration. During the supply relationship, we provide batch-specific quality documentation before shipment, respond to quality-related inquiries within two business days, and provide annual product quality review summaries consolidating batch data across the supply period. For customers undergoing regulatory inspections (FDA, EDQM, or national authority inspections), we provide audit support documentation and can facilitate communication with the manufacturing partner if the inspector requests manufacturing site information.
Post-delivery quality support includes investigation of any quality-related observations reported by the customer, coordination of retention sample testing if needed, and support for customer change control evaluations when process changes at the manufacturing site may affect the API supplied. This ongoing quality support distinguishes our china api quality management approach from transactional suppliers who consider their quality responsibility complete when the shipment leaves the warehouse.
Continuous improvement is the mechanism by which KingWish's quality system evolves in response to operational experience, regulatory developments, and customer feedback. Our quality roadmap is structured around annual objectives that address the quality system elements most relevant to our role as a pharmaceutical API procurement partner.
Supplier quality development is a continuous improvement priority. Manufacturing partners whose audit scores are satisfactory but not outstanding are assigned specific improvement objectives with defined milestones. KingWish quality personnel monitor progress against these objectives through quarterly check-ins and verify completion at the next audit cycle. The goal is not to maintain a minimum acceptable quality level but to raise the quality standard of every manufacturing partner over time, because improvements at the manufacturing site translate directly into more reliable supply for our customers.
Documentation digitization is a medium-term objective on the quality roadmap. Paper-based batch records and CoAs, while compliant with current GMP regulations, are less efficient to review, transmit, and archive than electronic systems. KingWish is progressively transitioning to electronic quality documentation systems that will enable faster documentation turnaround, more thorough data trending analysis, and easier documentation retrieval for regulatory inquiries. Customer-specific quality portals that provide real-time access to batch documentation and quality metrics are under development as part of this digitization initiative.
Regulatory horizon scanning ensures that KingWish stays ahead of changing quality requirements. We monitor ICH guideline revisions, pharmacopoeia monograph updates (USP, EP, ChP), and regulatory authority guidance documents (FDA, EMA, NMPA) for changes that affect API quality requirements. When a pharmacopoeia monograph is updated with a new impurity limit or a new test requirement, we proactively notify customers who purchase that API and coordinate with the manufacturing partner to implement any required method updates or specification changes before the implementation date. The KingWish Pharmaceutical Glossary provides definitions of relevant ICH guidelines and pharmacopoeia references for buyers who wish to understand the regulatory foundation of these requirements.
Before any shipment leaves the manufacturer's warehouse, KingWish offers a pre-shipment quality review that allows the buyer to review the batch documentation package including CoA, MSDS, stability data, and any applicable third-party test reports. This review is conducted at no additional cost and does not delay shipment when the review is initiated early in the production cycle.
To request a pre-shipment quality review, contact KingWish with the API name, target quantity, and target pharmacopoeia (USP, EP, or ChP). Our quality team will provide the current quality documentation template and confirm the expected documentation delivery timeline. For repeat buyers, we can establish standing instructions for pre-shipment documentation delivery so that documentation arrives on a predictable schedule aligned with the buyer's incoming quality control workflow. Buyers who import pharmaceutical API from China for use in regulated-market drug products are encouraged to integrate the pre-shipment quality review into their supplier qualification and ongoing monitoring procedures. For guidance on broader import requirements, see our How to Import Pharmaceutical API from China guide.